Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel)
work together in treating patients with Richter's syndrome. Richter's syndrome occurs
when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an
aggres...
Age: 18 years - 66+
Gender: All
A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended
Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-80948543 in Part A (Dose
Escalation) and to further characterize the safety of JNJ-80948543 at the putative ...
Age: 18 years - 66+
Gender: All
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative
recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of
administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize
the safety of JN...
Age: 18 years - 66+
Gender: All
A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation
A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed
or refractory AML.
Age: 18 years - 66+
Gender: All
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
This phase III trial compares early treatment with venetoclax and obinutuzumab versus
delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed
high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a
class of...
Age: 18 years - 66+
Gender: All
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell
non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate
the safety of JNJ-64264681 at the RP2D(s) in Part 2.
Age: 18 years - 66+
Gender: All
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for
the first time. The trial includes a Main Study and four sub-studies. In the Main Study
(including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in
patie...
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
The purpose of this study is to determine the most appropriate dose for the combination of
ibrutinib and pembrolizumab and to see if the combination is active for the disease. The
study will monitor for any side effects and if the combination of ibrutinib and pembro...
Age: 18 - 99 years
Gender: All
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating younger
patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia
that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab
ozogami...
Age: 1 year - 21 years
Gender: All